<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part5">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>5</PartID>
        <PartNumber>Part IV</PartNumber>
        <PartSequenceNumber>5</PartSequenceNumber>
        <PartTitle>Bone Metastasis</PartTitle>
        <PartChapterCount>5</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap22" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>22</ChapterID>
          <ChapterNumber>Chapter 22</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_22</ChapterDOI>
          <ChapterSequenceNumber>22</ChapterSequenceNumber>
          <ChapterTitle Language="En">Pathophysiology of Prostate Cancer Bone Metastasis</ChapterTitle>
          <ChapterFirstPage>245</ChapterFirstPage>
          <ChapterLastPage>254</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>5</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author AffiliationIDS="Aff1_22" CorrespondingAffiliationID="Aff1_22">
              <AuthorName DisplayOrder="Western">
                <GivenName>Evan</GivenName>
                <GivenName>T.</GivenName>
                <FamilyName>Keller</FamilyName>
              </AuthorName>
              <Contact>
                <Email>etkeller@umich.edu</Email>
              </Contact>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Christopher</GivenName>
                <GivenName>L.</GivenName>
                <FamilyName>Hall</FamilyName>
              </AuthorName>
            </Author>
            <Affiliation ID="Aff1_22">
              <OrgDivision>Department of Urology</OrgDivision>
              <OrgName>University of Michigan</OrgName>
              <OrgAddress>
                <City>Ann Arbor</City>
                <State>MI</State>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_22" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Prostate cancer (CaP) is the most frequently diagnosed cancer in men and the second leading cause of cancer death among men in the United States. The most common site of CaP metastasis is the bone with skeletal metastases identified in virtually all patients dying from CaP. Skeletal metastasis in CaP patients results in bone pain, impaired mobility, pathological fracture, spinal cord compression, and symptomatic hypercalcemia. The mechanisms through which CaP metastasizes to and interacts with bone are not well-defined. There are both osteolytic and osteoblastic components of CaP metastasis. A variety of factors including receptor activator of NFkB ligand (RANKL), interleukin-6 (IL-6), matrix metalloproteinases (MMPs), and parathyroid hormone-related protein (PTHrP) have been implicated in the osteolytic activity of CaP. In terms of osteoblastic metastasis, many proteins including bone morphogenetic proteins (BMPs), Wnts, and endothelin-1 (ET-1) have been implicated as CaP-produced osteoblastic factors. Once in the bone microenvironment, the CaP cells interact with the bone resulting in an overall balance that shifts the CaP from an osteolytic to an osteoblastic activity. Understanding the mechanisms through which CaP metastasizes and interacts with bone will hopefully lead to therapies for CaP bone metastasis.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Prostate cancer</Keyword>
            <Keyword>Bone metastasis</Keyword>
            <Keyword>RANKL</Keyword>
            <Keyword>Bone morphogenetic protein</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1" Type="Introduction">
            <Heading>Introduction</Heading>
            <Para TextBreak="No">Prostate cancer (CaP) is the most frequently diagnosed cancer in men and the second leading cause of cancer death among men in the United States [<CitationRef CitationID="CR1_22">1</CitationRef>]. The most common site of CaP metastasis is the bone with skeletal metastases identified in virtually all patients dying from CaP [<CitationRef CitationID="CR2_22">2</CitationRef>]. Skeletal metastasis in CaP patients results in bone pain, impaired mobility, pathological fracture, spinal cord compression, and symptomatic hypercalcemia [<CitationRef CitationID="CR3_22">3</CitationRef>]. Significant advances in the diagnosis and management of primary CaP have been made that have improved cure rates; however, once disease becomes advanced, it remains incurable. In the case of metastatic disease, most therapies are palliative and include hormonal therapy, pharmacological management of bone pain, radiotherapy for pain and spinal cord compression. It is critical that a solid understanding of the pathophysiology of CaP skeletal metastatic process is developed to provide the basis for creating strategies to prevent or diminish their occurrence and associated complications.</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>Bone Biology</Heading>
            <Para TextBreak="No">An understanding of the basic components and functions of bone is critical to provide a basis for understanding bone metastasis. The skeleton functions as a framework for the body, the main site for hematopoiesis, a reservoir for calcium, and a structure for muscle attachments. The skeleton is divided into the appendicular skeleton consisting of the limbs and the axial skeleton consisting of the skull, vertebral column, ribs, and sternum. The skeleton is a dynamic organ and is constantly remodeling in response to stress placed on it [<CitationRef CitationID="CR4_22">4</CitationRef>]. A typical bone consists of both a cortical (also known as compact bone) component and a trabecular (also known as spongy or cancellous bone) component (Fig. <InternalRef RefID="Fig1">22.1</InternalRef>). Cortical bone is made of concentric layers of bone that forms a hard outer shell and typically found in the shafts of appendicular bone. Trabecular bone consists of struts of bone found within the concentric bone shell and found in through the metaphyses and epiphyses of bones.<Figure Category="Standard" Float="Yes" ID="Fig1">
                <Caption Language="En">
                  <CaptionNumber>Fig. 22.1</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Anatomy of bone. Longitudinal section of a long bone</SimplePara>
                  </CaptionContent>
                </Caption>
                <MediaObject ID="MO1_22">
                  <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-829-4_22_Fig1_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                </MediaObject>
              </Figure>
            </Para>
            <Para TextBreak="No">Bone is a very active substance that is composed of mineralized and nonmineralized components [<CitationRef CitationID="CR5_22">5</CitationRef>]. Collagen is the main protein constituent of the unmineralized extracellular matrix (also known as osteoid) and is considered to provide the framework for mineralization. Other proteins that contribute to the osteoid include osteopontin, bone sialoprotein (BSP), osteonectin, and alkaline phosphatase (BAP) [<CitationRef CitationID="CR6_22">6</CitationRef>, <CitationRef CitationID="CR7_22">7</CitationRef>]. Bone mineral consists of primarily calcium and phosphate that forms an organized crystalline structure called hydroxyapatite. When bone is initially formed, the collagen fibers are laid down in a disorganized interwoven fashion forming what is termed as woven bone [<CitationRef CitationID="CR8_22">8</CitationRef>]. As bone matures, the collagen fibrils become lined up in a parallel fashion forming lamellar bone [<CitationRef CitationID="CR9_22">9</CitationRef>]. Woven bone is not as strong in terms of biomechanical properties as lamellar bone [<CitationRef CitationID="CR10_22">10</CitationRef>]. As bone becomes more mineralized, its strength increases up to a point, but further mineralization beyond an optimal level reduces bone elasticity leading to the inability of the bone to respond to certain stresses which then results in fragile bone that is predisposed to fracture [<CitationRef CitationID="CR11_22">11</CitationRef>].</Para>
            <Para TextBreak="No">The key cells that are involved in bone production and remodeling are the osteoblasts and osteoclasts. Osteoblasts are the cells that lay down collagen matrix and promote mineralization. Osteoblast production requires specific transcription factors. RUNX2 (also called Cbfa1 and OSF2), a member of the runt/Cbfa family of transcription factors, was first identified as the nuclear protein binding to an osteoblast-specific cis-acting element activating the expression of osteocalcin [<CitationRef CitationID="CR12_22">12</CitationRef>]. RUNX2 was shown to regulate the expression of all the major genes expressed by osteoblasts and be a key regulator of osteoblast differentiation in vivo [<CitationRef CitationID="CR13_22">13</CitationRef>].</Para>
            <Para TextBreak="No">As opposed to osteoblasts that produce mineralized matrix, osteoclasts are multinucleated cells responsible for bone resorption that dissolve the mineralized hydroxyapatite and degrade nonmineralized bone matrix [<CitationRef CitationID="CR14_22">14</CitationRef>]. They are derived from the colony-forming unit granulocyte-macrophage (CFU-GM) hematopoietic precursor cells. Several factors promote osteoclastogenesis including growth factors and cytokines. Both colony stimulating factor (CSF-1) and interleukins-1 and -6 (IL-1 and IL-6) expand the osteoclast precursor pool. TNF-alpha promotes conversion of the promonocyte to a committed osteoclast precursor [<CitationRef CitationID="CR15_22">15</CitationRef>].</Para>
            <Para TextBreak="No">Although several factors promote osteoclastogenesis, one factor that is required for production of mature osteoclasts is receptor activator of nuclear factor kappa B ligand (RANKL). A member of the tumor necrosis factor family, RANKL is initially expressed by bone marrow stromal cells, osteoblasts, and activated-T cells. RANKL is most commonly a membrane anchored molecule; however, a small fraction of RANKL is released through proteolytic cleavage from the cell surface as a soluble 245 amino acid homotrimeric molecule (sRANKL) [<CitationRef CitationID="CR16_22">16</CitationRef>]. Both soluble and membrane bound RANKL promote osteoclast formation and activation by binding to RANK on the osteoclast precursor membrane that has the characteristics of a monocyte [<CitationRef CitationID="CR17_22">17</CitationRef>]. RANKL binding to RANK induces NFkappaB and Fos activation [<CitationRef CitationID="CR18_22">18</CitationRef>].</Para>
            <Para TextBreak="No">In addition to RANKL and RANK, another key modulator of osteoclastogenesis is osteoprotegerin (OPG) (also known as osteoclastogenesis inhibitory factor-OCIF) [<CitationRef CitationID="CR19_22">19</CitationRef>, <CitationRef CitationID="CR20_22">20</CitationRef>]. OPG serves as a decoy receptor that binds RANKL and thus blocks its ability to bind to RANK and induce osteoclastogenesis. In contrast to RANKL and RANK, whose expression is mainly restricted at low levels to the skeletal and immune systems, OPG is expressed in a variety of tissues, such as liver, lung, heart, kidney, stomach, intestines, skin, and calvaria in mice and lung, heart, kidney, and placenta in humans. In bone, OPG is mainly produced by osteoblastic lineage cells, and its expression increases as the cells become more differentiated [<CitationRef CitationID="CR21_22">21</CitationRef>]. Several factors including, 1,25-dihydroxyvitamin D3, interleukin-1-β (IL-1-β), tumor necrosis factor-α (TNF-α), and bone morphogenetic protein 2 (BMP-2) induce OPG mRNA expression in human osteoblast cell lines [<CitationRef CitationID="CR22_22">22</CitationRef>]. Administration of recombinant OPG to normal rodents resulted in increased bone mass [<CitationRef CitationID="CR19_22">19</CitationRef>] and completely prevented ovariectomy-induced bone loss without apparent adverse skeletal and extraskeletal side effects [<CitationRef CitationID="CR19_22">19</CitationRef>]. It appears that the balance of the ratio of RANKL to OPG is very important in controlling the overall activity (i.e., lysis vs. no lysis) that will be observed.</Para>
            <Para TextBreak="No">When initiating bone resorption, osteoclasts become polarized, and three distinct membrane domains appear: a ruffled border, a sealing zone, and a functional secretory domain [<CitationRef CitationID="CR14_22">14</CitationRef>]. The actin cytoskeleton forms an attachment ring at the sealing zone that anchors the osteoclast to the bone matrix. The ruffled border appears inside the sealing zone and vesicle transport to the ruffled border delivers hydrochloric acid and proteases to an area between the ruffled border and the bone surface called the resorption lacuna [<CitationRef CitationID="CR14_22">14</CitationRef>]. In this extracellular compartment, crystalline hydroxyapatite is dissolved by acid, and a mixture of proteases degrades the organic matrix. The degradation products of collagen and other matrix components are endocytosed, transported through the cell, and exocytosed through a functional secretory domain [<CitationRef CitationID="CR23_22">23</CitationRef>].</Para>
            <Para TextBreak="No">Proteases that are important mediators of osteoclastic activity include cathepsin K and metalloproteinases. Cathepsin K can cleave bone proteins such as Type I collagen, osteopontin, and osteonectin [<CitationRef CitationID="CR24_22">24</CitationRef>]. Overexpression of cathepsin K in the mouse results in accelerated bone turnover [<CitationRef CitationID="CR25_22">25</CitationRef>], whereas knockout of cathepsin K results in retarded bone matrix degradation and osteopetrosis [<CitationRef CitationID="CR26_22">26</CitationRef>]. In addition to the proteases, acid is secreted from osteoclasts to resorb the mineralized matrix. Acid is believed to be secreted through vacuolar H(+)-ATPase-dependent pumps present on the osteoclasts ruffled membranes [<CitationRef CitationID="CR27_22">27</CitationRef>]. Several hormones regulate acid secretion, including parathyroid hormone, which increases acid secretion and calcitonin, which decreases acid secretion. Carbonic anhydrase II appears to be an important mediator of acid production because acetazolamide, a carbonic anhydrase inhibitor-based diuretic, can block bone resorption [<CitationRef CitationID="CR28_22">28</CitationRef>]. Another diuretic, indapamide, increased osteoblast proliferation and decreased bone resorption, at least in part, by decreasing osteoclast differentiation via a direct effect on hematopoietic precursors in vitro [<CitationRef CitationID="CR29_22">29</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec3">
            <Heading>Bone Remodeling</Heading>
            <Para TextBreak="No">Bone remodeling is the cyclical replacement of old bone by new bone. Remodeling serves to maintain bones’ mechanical stability and allows it to perform its metabolic actions. In each cycle, a defined volume of bone is removed by osteoclastic resorption and subsequently replaced by osteoblastic formation at the same location. Remodeling is carried out by elongated structures known as basic multicellular units (BMU; sometimes called bone metabolic units) that travel through or across the surface of bone. In the human, each BMU lasts about 6 months, with continued sequential recruitment of new osteoclasts and osteoblasts [<CitationRef CitationID="CR30_22">30</CitationRef>]. The BMU is initiated by osteoclasts resorbing old bone followed by osteoblasts synthesizing new bone in the resorption lacunae (areas resorbed by osteoclasts).</Para>
          </Section1>
          <Section1 ID="Sec4">
            <Heading>Osteoblastic Bone Metastases</Heading>
            <Para TextBreak="No">Many functions contribute to the ability of CaP cells to target to bone including homing and attachment to bone and invasion into bone. Once in the bone, CaP skeletal metastases are most often characterized as radiographically osteoblastic (i.e., increased bone density on the radiograph) as opposed to osteolytic. Other tumors, such as breast cancer, can form osteoblastic lesions; however, these occur less frequently [<CitationRef CitationID="CR31_22">31</CitationRef>]. In spite of the radiographic osteoblastic appearance, it is clear from histological evidence that CaP metastases form a heterogeneous mixture of osteolytic and osteoblastic lesions although osteoblastic lesions are predominate [<CitationRef CitationID="CR32_22">32</CitationRef>]. Recent evidence shows that osteoblastic metastases form on trabecular bone at sites of previous osteoclastic resorption, and that such resorption may be required for subsequent osteoblastic bone formation [<CitationRef CitationID="CR33_22">33</CitationRef>]. These findings suggest that CaP induces bone production through an overall increase in bone remodeling, which in the nonpathologic state is a balance between osteoclast resorption of bone, followed by osteoblast-mediated replacement of resorbed bone. In the case of CaP, it appears the induction of osteoblast-mediated mineralization outweighs the increase in osteoclast resorption resulting in an overall formation of osteoblastic lesions. The osteoblastic lesions result in overall weakening of the bone due to the production of woven bone and hypermineralization. Thus, the combination of underlying osteolysis and production of weak bone leads to a predisposition to fracture. The mechanisms through which CaP cells promote bone mineralization remain poorly understood.</Para>
            <Para TextBreak="No">CaP cells produce a variety of factors that have direct or indirect osteogenic properties (Table <InternalRef RefID="Tab1">22.1</InternalRef>). Some of these factors, such as bone morphogenetic proteins (BMP) [<CitationRef CitationID="CR34_22">34</CitationRef>] and enodothlin-1 (ET-1) [<CitationRef CitationID="CR35_22">35</CitationRef>] may directly stimulate differentiation of osteoblast precursors to mature mineral-producing osteoblasts. Other factors such as parathyroid hormone-related protein (PTHrP) may work through inhibition of osteoblast apoptosis [<CitationRef CitationID="CR36_22">36</CitationRef>]. Additionally, there are proteins that may work indirectly to enhance bone production, such as the serine proteases, prostate specific antigen (PSA), and urinary plasminogen activator (uPA), which can activate latent forms of osteogenic proteins, such as transforming growth factor-β (TFG-β) [<CitationRef CitationID="CR37_22">37</CitationRef>]. Finally, some molecules, such as osteoprotegerin (OPG) [<CitationRef CitationID="CR38_22">38</CitationRef>] and ET-1 (in a dual role with its osteoblast-stimulating activity) [<CitationRef CitationID="CR39_22">39</CitationRef>] can enhance osteosclerosis through inhibiting osteoclastogenesis. In spite of this gamut of putative mediators of CaP-induced osteosclerosis, the authors are unaware of in vivo studies that unequivocally demonstrate their role in this process. The large number of factors suggest that several of these osteogenic factors work in concert to produce maximal bone production.<Table Float="Yes" ID="Tab1">
                <Caption Language="En">
                  <CaptionNumber>Table 22.1</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Osteogenic factors produced by prostate cancer cells</SimplePara>
                  </CaptionContent>
                </Caption>
                <tgroup cols="2">
                  <colspec colname="c1" colnum="1"/>
                  <colspec colname="c2" colnum="2"/>
                  <thead>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Factor</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>References</SimplePara>
                      </entry>
                    </row>
                  </thead>
                  <tbody>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Bone morphogenetic proteins (BMP)</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>[<CitationRef CitationID="CR34_22">34</CitationRef>, <CitationRef CitationID="CR96_22">96</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Endothelin-1 (ET-1)</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>[<CitationRef CitationID="CR97_22">97</CitationRef>-<CitationRef CitationID="CR100_22">100</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Insulin-like growth factors (IGF)</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>[<CitationRef CitationID="CR101_22">101</CitationRef>, <CitationRef CitationID="CR102_22">102</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Interleukin-1 and -6</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>[<CitationRef CitationID="CR103_22">103</CitationRef>, <CitationRef CitationID="CR104_22">104</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Osteoprotegerin (OPG)</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>[<CitationRef CitationID="CR38_22">38</CitationRef>, <CitationRef CitationID="CR105_22">105</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Parathyroid hormone-related peptide (PTHrP)</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>[<CitationRef CitationID="CR36_22">36</CitationRef>, <CitationRef CitationID="CR106_22">106</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Transforming growth factor-β (TFG-β)</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>[<CitationRef CitationID="CR107_22">107</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Urinary plasminogen activator (urokinase)</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>[<CitationRef CitationID="CR108_22">108</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Vascular endothelial growth factor (VEGF)</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>[<CitationRef CitationID="CR109_22">109</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Wnts</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>[<CitationRef CitationID="CR110_22">110</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                  </tbody>
                </tgroup>
              </Table>
            </Para>
          </Section1>
          <Section1 ID="Sec5">
            <Heading>Osteoclastic Bone Metastases</Heading>
            <Para TextBreak="No">Osteolytic activity is a key component of CaP bone metastasis and is regulated by a critical factor, RANKL. Several lines of evidence support the role of RANKL in prostate cancer-mediated osteolysis. Although a bone metastatic prostate cancer cell line has been shown to express OPG [<CitationRef CitationID="CR40_22">40</CitationRef>], that same line overexpresses RANKL [<CitationRef CitationID="CR41_22">41</CitationRef>]. Additionally, in normal prostate, OPG protein was detected in luminal, epithelial, and stromal cells (5–65% and 15–70%, respectively), and RANKL immunoreactivity was observed in 15–50% of basal epithelial cells, 40–90% of luminal epithelial cells, and 70–100% of stromal cells [<CitationRef CitationID="CR42_22">42</CitationRef>]. OPG was not detected in eight of ten primary CaP specimens, but RANKL was heterogeneously expressed in 10 of 11 CaP specimens [<CitationRef CitationID="CR42_22">42</CitationRef>]. Importantly, the percentage of tumor cells expressing OPG and RANKL was significantly increased in all CaP bone metastases compared with nonosseous metastases or primary CaP. The presence of RANKL in CaP tissues has been shown to indicate poor prognosis [<CitationRef CitationID="CR43_22">43</CitationRef>, <CitationRef CitationID="CR44_22">44</CitationRef>]. Serum OPG levels are elevated in patients with advanced prostate cancer compared to less advanced prostate cancer [<CitationRef CitationID="CR45_22">45</CitationRef>]. In one study, serum RANKL levels were not altered, although the RANKL–OPG was altered in these patients due to changes in OPG [<CitationRef CitationID="CR46_22">46</CitationRef>]. It is possible that RANKL is only expressed locally at the skeletal metastatic site and therefore not detectable in the serum. Regardless, taken together, these observations suggest that the RANKL–OPG axis may play an important role in prostate cancer bone metastases. Further support for this possibility was demonstrated by the observation that administration of OPG prevented establishment of mixed osteoblastic/osteolytic prostate cancer cells in the bones of SCID mice, although it had no effect on establishment of subcutaneous tumors in the same mice [<CitationRef CitationID="CR41_22">41</CitationRef>]. However, in another study, OPG administration did not prevent establishment of an osteoblastic prostate cancer tumor although it slowed the tumor growth [<CitationRef CitationID="CR47_22">47</CitationRef>]. OPG also diminished the progression of established osteoblastic prostate cancer in human bone implants in mice [<CitationRef CitationID="CR48_22">48</CitationRef>]. Taken together, these studies suggest that OPG can inhibit prostate tumor growth in bone.</Para>
            <Para TextBreak="No">Matrix metalloproteinases (MMPs), a family of enzymes whose primary function is to degrade the extracellular matrix, play a role in bone remodeling. This activity occurs in the absence of osteoclasts [<CitationRef CitationID="CR49_22">49</CitationRef>] suggesting that MMPs have a direct resorptive effect. Several have the ability to degrade the nonmineralized matrix of bone including MMP1, MMP9, and MMP13, which are collagenases. Other MMPs such as stromelysin (MMP3) activate MMP1. Through their proteolytic activity, MMPs contribute to metastatic invasion, including destruction of bone [<CitationRef CitationID="CR50_22">50</CitationRef>].</Para>
            <Para TextBreak="No">Prostate carcinomas and their cell lines express a large number of MMPs. Levels of MMP9 secretion in primary prostate cancer cultures increased with Gleason histological grade [<CitationRef CitationID="CR51_22">51</CitationRef>]. Active MMP9 species were detected in 15 cultures (31%) of primary prostate cancer tissues. The presence of the mineralized matrix has been shown to induce MMP9 expression from prostate carcinoma cells [<CitationRef CitationID="CR52_22">52</CitationRef>]. MMP12 has been shown to be upregulated in CaP, and knockdown of MMP12 inhibited the ability of a CaP cell line perform in vitro invasion [<CitationRef CitationID="CR53_22">53</CitationRef>].</Para>
            <Para TextBreak="No">The initial functional data that suggested CaP bone metastasis modulate bone remodeling through MMPs was provided by in vitro studies. Specifically, blocking MMP activity with 1,10-phenanthroline, a MMP inhibitor, diminished bone matrix degradation induced by PC-3 cells in vitro [<CitationRef CitationID="CR54_22">54</CitationRef>, <CitationRef CitationID="CR55_22">55</CitationRef>]. Matrilysin (MMP7) has been shown to be upregulated in DU-145 prostate cancer cells and can enhance their invasive ability. Monoclonal antibody targeting the cytokine interleukin-6 (IL-6) has been shown to increase promatrilysin expression in DU-145 cultures [<CitationRef CitationID="CR56_22">56</CitationRef>]. This suggests that IL-6, which is increased in prostate cancer (reviewed in [<CitationRef CitationID="CR57_22">57</CitationRef>]), enhances prostate cancer invasion through production of MMP-7.</Para>
            <Para TextBreak="No">The importance of MMPs in bone metastasis has been further confirmed in vivo. An MMP inhibitor, batimistat, has been shown to inhibit development bone resorption in vitro and in vivo in murine models of breast [<CitationRef CitationID="CR58_22">58</CitationRef>] and CaP [<CitationRef CitationID="CR59_22">59</CitationRef>]. The mechanism through which CaP-produced MMPs induce bone resorption is not clear; however, it appears to involve induction of osteoclastogenesis as inhibition of MMPs reduced the number of osteoclasts associated with prostate tumor growth in human bone implants in mice [<CitationRef CitationID="CR59_22">59</CitationRef>]. Additionally, the bisphosphonate alendronate blocked MMP production from PC-3 cells [<CitationRef CitationID="CR60_22">60</CitationRef>]. This was associated with diminished establishment of bone metastasis in mice injected with PC-3 tumors [<CitationRef CitationID="CR49_22">49</CitationRef>].</Para>
            <Para TextBreak="No">PTHrP, a protein with limited homology to parathyroid hormone (PTH), was originally identified as a tumor-derived factor responsible for humoral hypercalcemia of malignancy (HHM). PTH and PTHrP bind to the same receptor (the PTH-1 receptor) and evoke the same biological activity due to similarities in their steric configurations at the region of 25–34 amino acids. Patients with solid tumors and hypercalcemia have increased serum PTHrP in 80% of the cases, emphasizing the impact of this peptide to increase bone resorption and renal tubular resorption of calcium [<CitationRef CitationID="CR61_22">61</CitationRef>]. Subsequent to its characterization in HHM, PTHrP was found to be produced by many normal tissues including, epithelium, lactating mammary gland, and cartilage where it has an autocrine, paracrine, or intracrine role [<CitationRef CitationID="CR61_22">61</CitationRef>].</Para>
            <Para TextBreak="No">PTHrP is an attractive candidate for influencing CaP growth. PTHrP is produced by normal prostate epithelial cells, from which CaP arises and PTHrP is found in the seminal fluid [<CitationRef CitationID="CR62_22">62</CitationRef>, <CitationRef CitationID="CR63_22">63</CitationRef>]. PTHrP has been immunohistochemically identified in prostate carcinoma tissue in patients with clinically localized disease [<CitationRef CitationID="CR64_22">64</CitationRef>], is found in higher levels in prostate intraepithelial neoplasia than in normal prostate epithelium, is found in higher levels in prostate carcinoma than in benign prostatic hyperplasia [<CitationRef CitationID="CR65_22">65</CitationRef>, <CitationRef CitationID="CR66_22">66</CitationRef>], and is found in human metastatic lesions in bone [<CitationRef CitationID="CR67_22">67</CitationRef>]. However, in some studies, expression of PTHrP receptor in prostate cancer appears to be more consistent than expression of PTHrP itself [<CitationRef CitationID="CR68_22">68</CitationRef>]. Overexpression of ras oncogene in immortalized prostate epithelial cells has been shown to promote PTHrP expression [<CitationRef CitationID="CR69_22">69</CitationRef>]. This may account for the increased expression of PTHrP as the cells progress to a malignant phenotype.</Para>
            <Para TextBreak="No">There is evidence that PTHrP can act as an autocrine growth factor for CaP cells in vitro [<CitationRef CitationID="CR62_22">62</CitationRef>] although it does not affect proliferation of normal prostate cells [<CitationRef CitationID="CR70_22">70</CitationRef>]. PTHrP production by primary prostatic tumors is associated with increased tumor size and rate of growth in an animal model [<CitationRef CitationID="CR67_22">67</CitationRef>] suggesting that PTHrP acts in an autocrine or intracrine mechanism to promote tumor growth. In contrast, in this same model and in an intracardiac injection model of CaP, PTHrP was not associated with an increase in metastatic potential [<CitationRef CitationID="CR67_22">67</CitationRef>, <CitationRef CitationID="CR71_22">71</CitationRef>]. This suggests that PTHrP is important in the bone microenvironment where target cells with receptors are present (osteoblasts); it may play a critical role in the bone response to CaP. PTHrP expression has been localized to CaP tissues demonstrating it is present in the bone microenvironment [<CitationRef CitationID="CR72_22">72</CitationRef>]. Overexpression of PTHrP in CaP cells has been shown to induce osteolytic lesions in the bone of rats [<CitationRef CitationID="CR73_22">73</CitationRef>] although the level of expression may not directly correlate with the degree of osteolysis [<CitationRef CitationID="CR71_22">71</CitationRef>]. PTHrP also promotes monocytes activity at CaP sites, which can induce osteolytic activity [<CitationRef CitationID="CR74_22">74</CitationRef>]. All these data suggest that PTHrP has a critical role in the local bone microenvironment of metastatic prostate carcinoma; but what this precise role is has yet to be determined.</Para>
            <Para TextBreak="No">IL-6 belongs to the “interleukin-6 type cytokine” family that also includes leukemia inhibitory factor, interleukin-11, ciliary neurotrophic factor, cardiotrophin-1, and oncostatin M [<CitationRef CitationID="CR75_22">75</CitationRef>]. Many physiologic functions are attributed to IL-6 including promotion of antibody production from B lymphocytes, modulation of hepatic acute phase reactant synthesis, promotion of osteoclastic-mediated bone resorption, and induction of thrombopoiesis [<CitationRef CitationID="CR76_22">76</CitationRef>]. IL-6 mediates its activity through the IL-6 receptor complex, which is composed of two components; an 80 Kd transmembrane receptor (IL-6Rp80, IL-6R, α-subunit) that specifically binds IL-6, but has no signaling capability and a 130 Kd membrane glycoprotein (gp130) that mediates signal transduction following IL-6R binding [<CitationRef CitationID="CR77_22">77</CitationRef>]. In addition to the transmembrane IL-6R, a soluble form of IL-6R (sIL-6R) exists that is produced by either proteolytic cleavage of the 80 kDa subunit [<CitationRef CitationID="CR78_22">78</CitationRef>, <CitationRef CitationID="CR79_22">79</CitationRef>] or differential splicing of mRNA [<CitationRef CitationID="CR80_22">80</CitationRef>]. Although the sIL-6R does not possess a transmembrane component, it can still bind to IL-6 and the ligand bound sIL-6R·IL-6 complex activates signal transduction and biological responses through membrane-bound gp130 [<CitationRef CitationID="CR81_22">81</CitationRef>].</Para>
            <Para TextBreak="No">Multiple studies have demonstrated that IL-6 is elevated in the sera of patients with metastatic prostate cancer [<CitationRef CitationID="CR82_22">82</CitationRef>-<CitationRef CitationID="CR84_22">84</CitationRef>]. Adler et al. [<CitationRef CitationID="CR82_22">82</CitationRef>] demonstrated that serum levels of IL-6 and transforming growth factor-β1 are elevated in patients with metastatic prostate cancer, and that these levels correlate with tumor burden as assessed by serum PSA or clinically evident metastases. In a similar fashion, Drachenberg et al. [<CitationRef CitationID="CR85_22">85</CitationRef>] reported elevated serum IL-6 levels in men with castrate-resistant prostate cancer compared to normal controls, benign prostatic hyperplasia, prostatitis, and localized or recurrent disease. In an animal model, prostate tumor cells injected next to human bones implanted in the limb of mice demonstrated IL-6 expression [<CitationRef CitationID="CR86_22">86</CitationRef>]. In addition to IL-6, the IL-6R has been identified in human normal prostate and prostate carcinoma tissue [<CitationRef CitationID="CR87_22">87</CitationRef>, <CitationRef CitationID="CR88_22">88</CitationRef>].</Para>
            <Para TextBreak="No">The secretion of IL-6 by prostate cancer cells in the bone microenvironment may impact bone remodeling (reviewed in [<CitationRef CitationID="CR89_22">89</CitationRef>]). IL-6 promotes osteoclastogenesis [<CitationRef CitationID="CR90_22">90</CitationRef>] most likely through increasing osteoclastogenic precursors. IL-6-mediated osteoclastogenesis is directly related to the level of gp130 present on the precursor cells [<CitationRef CitationID="CR91_22">91</CitationRef>]. It appears that IL-6-mediated osteoclastogenesis is independent of promoting RANKL expression [<CitationRef CitationID="CR92_22">92</CitationRef>]. However, IL-6 has been shown to potentiate PTHrP-induced osteoclastogenesis [<CitationRef CitationID="CR93_22">93</CitationRef>, <CitationRef CitationID="CR94_22">94</CitationRef>]. Administration of anti-IL-6 antibody has been shown to diminish the growth of subcutaneously injected prostate cancer cells in nude mice, thus demonstrating the potential utility of this compound in clinical prostate cancer [<CitationRef CitationID="CR95_22">95</CitationRef>]. These results strongly suggest that IL-6 may serve as a therapeutic target for the osteolytic component of prostate cancer skeletal metastases.</Para>
          </Section1>
          <Section1 ID="Sec6">
            <Heading>Summary</Heading>
            <Para TextBreak="No">Bone metastasis is a frequent and debilitating complication of men with CaP. The bone provides a unique environment that both fosters the development of metastases and responds to the CaP cells resulting in aberrant bone production that results in clinical symptoms. The interaction between the CaP cells and bone is complex (summarized in Fig. <InternalRef RefID="Fig2">22.2</InternalRef>). The CaP cells induce bone resorption, which promotes CaP growth and changes them to an osteoblastic-inducing phenotype. A variety of factors participate in the induction of bone resorption. It appears that RANKL is a key factor induced by CaP cells, which results in osteoclastogenesis. Additionally, a large number of CaP-produced factors have been implicated as being osteoblastic. Most likely, several factors work in unison to produce the overall osteoblastic phenotype. It is hoped that as we learn more about the pathophysiology of bone metastasis, we will be able to develop therapies to target this process.<Figure Category="Standard" Float="Yes" ID="Fig2">
                <Caption Language="En">
                  <CaptionNumber>Fig. 22.2</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Model of cross-talk between prostate carcinoma cells and the bone microenvironment. The bone produces chemotactic factors that attract prostate carcinoma cells to migrate (1) through the vascular system toward the skeleton. The bone marrow endothelial displays adhesion molecules that are complement those expressed by the prostate carcinoma cell, resulting in attachment of the cell (2). The prostate carcinoma cell extravasates and invades into the skeletal extracellular tissue (3), at which point it releases factors that stimulate osteoclastogenesis (4). The subsequent bone resorption is accompanied by release of growth factors that stimulate the prostate carcinoma proliferation (5). The progressing prostate carcinoma releases factors that promote osteoblast production and inhibit osteoblast apoptosis (6) resulting in production of woven bone and the characteristic osteosclerotic lesion. This process continues in a cyclical fashion with continued induction of osteoclastic activity, carcinoma cell proliferation, and bone production</SimplePara>
                  </CaptionContent>
                </Caption>
                <MediaObject ID="MO2_22">
                  <ImageObject Color="Color" FileRef="MediaObjects/978-1-60327-829-4_22_Fig2_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                </MediaObject>
              </Figure>
            </Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_22.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_22">
              <CitationNumber>1</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SH</Initials>
                  <FamilyName>Landis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Murray</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Bolden</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Wingo</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Cancer statistics, 1999</ArticleTitle>
                <JournalTitle>CA Cancer J Clin</JournalTitle>
                <VolumeID>49</VolumeID>
                <FirstPage>8</FirstPage>
                <LastPage>31</LastPage>
                <Occurrence Type="PID">
                  <Handle>10200775</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1M3hs1OrsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8–31.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_22">
              <CitationNumber>2</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RB</Initials>
                  <FamilyName>Shah</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Mehra</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Chinnaiyan</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>64</VolumeID>
                <FirstPage>9209</FirstPage>
                <LastPage>16</LastPage>
                <Occurrence Type="PID">
                  <Handle>15604294</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhtVOmsbzP</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64:9209–16.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_22">
              <CitationNumber>3</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Moul</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DR</Initials>
                  <FamilyName>Lipo</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Prostate cancer in the late 1990s: hormone refractory disease options</ArticleTitle>
                <JournalTitle>Urol Nurs</JournalTitle>
                <VolumeID>19</VolumeID>
                <FirstPage>125</FirstPage>
                <LastPage>31</LastPage>
                <Occurrence Type="PID">
                  <Handle>10633763</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3c%2FpvFGrsg%3D%3D</Handle>
                </Occurrence>
                <BibComments>quiz 32–3</BibComments>
              </BibArticle>
              <BibUnstructured>Moul JW, Lipo DR. Prostate cancer in the late 1990s: hormone refractory disease options. Urol Nurs 1999;19:125–31; quiz 32–3.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_22">
              <CitationNumber>4</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Augat</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>U</Initials>
                  <FamilyName>Simon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Liedert</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Claes</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Mechanics and mechano-biology of fracture healing in normal and osteoporotic bone</ArticleTitle>
                <JournalTitle>Osteoporos Int</JournalTitle>
                <VolumeID>16</VolumeID>
                <IssueID>Suppl 2</IssueID>
                <FirstPage>S36</FirstPage>
                <LastPage>43</LastPage>
                <Occurrence Type="PID">
                  <Handle>15372141</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Augat P, Simon U, Liedert A, Claes L. Mechanics and mechano-biology of fracture healing in normal and osteoporotic bone. Osteoporos Int 2005;16(Suppl 2):S36–43.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_22">
              <CitationNumber>5</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Hasegawa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CH</Initials>
                  <FamilyName>Turner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DB</Initials>
                  <FamilyName>Burr</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Contribution of collagen and mineral to the elastic anisotropy of bone</ArticleTitle>
                <JournalTitle>Calcif Tissue Int</JournalTitle>
                <VolumeID>55</VolumeID>
                <FirstPage>381</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>7866920</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXhvFWhtLo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hasegawa K, Turner CH, Burr DB. Contribution of collagen and mineral to the elastic anisotropy of bone. Calcif Tissue Int 1994;55:381–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_22">
              <CitationNumber>6</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Pinero</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Farach-Carson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RE</Initials>
                  <FamilyName>Devoll</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Aubin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Brunn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WT</Initials>
                  <FamilyName>Butler</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Bone matrix proteins in osteogenesis and remodelling in the neonatal rat mandible as studied by immunolocalization of osteopontin, bone sialoprotein, alpha 2HS-glycoprotein and alkaline phosphatase</ArticleTitle>
                <JournalTitle>Arch Oral Biol</JournalTitle>
                <VolumeID>40</VolumeID>
                <FirstPage>145</FirstPage>
                <LastPage>55</LastPage>
                <Occurrence Type="PID">
                  <Handle>7794128</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXlt1emsr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pinero GJ, Farach-Carson MC, Devoll RE, Aubin JE, Brunn JC, Butler WT. Bone matrix proteins in osteogenesis and remodelling in the neonatal rat mandible as studied by immunolocalization of osteopontin, bone sialoprotein, alpha 2HS-glycoprotein and alkaline phosphatase. Arch Oral Biol 1995;40:145–55.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_22">
              <CitationNumber>7</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Romanowski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Jundt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Termine</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Mark</FamilyName>
                  <Particle>von der</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Schulz</FamilyName>
                </BibAuthorName>
                <Year>1990</Year>
                <ArticleTitle Language="En">Immunoelectron microscopy of osteonectin and type I collagen in osteoblasts and bone matrix</ArticleTitle>
                <JournalTitle>Calcif Tissue Int</JournalTitle>
                <VolumeID>46</VolumeID>
                <FirstPage>353</FirstPage>
                <LastPage>60</LastPage>
                <Occurrence Type="PID">
                  <Handle>2364322</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3czgsVKrtA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Romanowski R, Jundt G, Termine JD, von der Mark K, Schulz A. Immunoelectron microscopy of osteonectin and type I collagen in osteoblasts and bone matrix. Calcif Tissue Int 1990;46:353–60.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_22">
              <CitationNumber>8</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Oguma</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Murakami</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Takahashi-Iwanaga</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Aoki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Ishii</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Early anchoring collagen fibers at the bone-tendon interface are conducted by woven bone formation: light microscope and scanning electron microscope observation using a canine model</ArticleTitle>
                <JournalTitle>J Orthop Res</JournalTitle>
                <VolumeID>19</VolumeID>
                <FirstPage>873</FirstPage>
                <LastPage>80</LastPage>
                <Occurrence Type="PID">
                  <Handle>11562136</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3MrhsVCmtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Oguma H, Murakami G, Takahashi-Iwanaga H, Aoki M, Ishii S. Early anchoring collagen fibers at the bone-tendon interface are conducted by woven bone formation: light microscope and scanning electron microscope observation using a canine model. J Orthop Res 2001;19:873–80.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_22">
              <CitationNumber>9</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Marotti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Muglia</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Palumbo</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Collagen texture and osteocyte distribution in lamellar bone</ArticleTitle>
                <JournalTitle>Ital J Anat Embryol</JournalTitle>
                <VolumeID>100</VolumeID>
                <IssueID>Suppl 1</IssueID>
                <FirstPage>95</FirstPage>
                <LastPage>102</LastPage>
                <Occurrence Type="PID">
                  <Handle>11322346</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Marotti G, Muglia MA, Palumbo C. Collagen texture and osteocyte distribution in lamellar bone. Ital J Anat Embryol 1995;100(Suppl 1):95–102.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_22">
              <CitationNumber>10</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Currey</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">The many adaptations of bone</ArticleTitle>
                <JournalTitle>J Biomech</JournalTitle>
                <VolumeID>36</VolumeID>
                <FirstPage>1487</FirstPage>
                <LastPage>95</LastPage>
                <Occurrence Type="PID">
                  <Handle>14499297</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3svktVOrsw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Currey JD. The many adaptations of bone. J Biomech 2003;36:1487–95.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_22">
              <CitationNumber>11</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Currey</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Tensile yield in compact bone is determined by strain, post-yield behaviour by mineral content</ArticleTitle>
                <JournalTitle>J Biomech</JournalTitle>
                <VolumeID>37</VolumeID>
                <FirstPage>549</FirstPage>
                <LastPage>56</LastPage>
                <Occurrence Type="PID">
                  <Handle>14996567</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Currey JD. Tensile yield in compact bone is determined by strain, post-yield behaviour by mineral content. J Biomech 2004;37:549–56.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_22">
              <CitationNumber>12</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Schinke</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Karsenty</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Characterization of Osf1, an osteoblast-specific transcription factor binding to a critical cis-acting element in the mouse Osteocalcin promoters</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>274</VolumeID>
                <FirstPage>30182</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>10514508</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXmvVajtb0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schinke T, Karsenty G. Characterization of Osf1, an osteoblast-specific transcription factor binding to a critical cis-acting element in the mouse Osteocalcin promoters. J Biol Chem 1999;274:30182–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_22">
              <CitationNumber>13</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Ducy</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Cbfa1: a molecular switch in osteoblast biology</ArticleTitle>
                <JournalTitle>Dev Dyn</JournalTitle>
                <VolumeID>219</VolumeID>
                <FirstPage>461</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="PID">
                  <Handle>11084646</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXovVSgsbY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ducy P. Cbfa1: a molecular switch in osteoblast biology. Dev Dyn 2000;219:461–71.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_22">
              <CitationNumber>14</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HK</Initials>
                  <FamilyName>Vaananen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Zhao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Mulari</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Halleen</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">The cell biology of osteoclast function</ArticleTitle>
                <JournalTitle>J Cell Sci</JournalTitle>
                <VolumeID>113</VolumeID>
                <IssueID>Pt 3</IssueID>
                <FirstPage>377</FirstPage>
                <LastPage>81</LastPage>
                <Occurrence Type="PID">
                  <Handle>10639325</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXhsFCqsLw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Vaananen HK, Zhao H, Mulari M, Halleen JM. The cell biology of osteoclast function. J Cell Sci 2000;113 (Pt 3):377–81.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_22">
              <CitationNumber>15</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HL</Initials>
                  <FamilyName>Uy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Mundy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BF</Initials>
                  <FamilyName>Boyce</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Tumor necrosis factor enhances parathyroid hormone-related protein- induced hypercalcemia and bone resorption without inhibiting bone formation in vivo</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>57</VolumeID>
                <FirstPage>3194</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>9242449</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXkvFKqs7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Uy HL, Mundy GR, Boyce BF, et al. Tumor necrosis factor enhances parathyroid hormone-related protein- induced hypercalcemia and bone resorption without inhibiting bone formation in vivo. Cancer Res 1997;57:3194–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_22">
              <CitationNumber>16</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Lum</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BR</Initials>
                  <FamilyName>Wong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Josien</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)- converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>274</VolumeID>
                <FirstPage>13613</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>10224132</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXjtFOksr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lum L, Wong BR, Josien R, et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)- converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 1999;274:13613–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_22">
              <CitationNumber>17</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Shalhoub</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Elliott</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Chiu</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Characterization of osteoclast precursors in human blood</ArticleTitle>
                <JournalTitle>Br J Haematol</JournalTitle>
                <VolumeID>111</VolumeID>
                <FirstPage>501</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>11122091</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3M7hs1KjsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Shalhoub V, Elliott G, Chiu L, et al. Characterization of osteoclast precursors in human blood. Br J Haematol 2000;111:501–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_22">
              <CitationNumber>18</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LC</Initials>
                  <FamilyName>Hofbauer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AE</Initials>
                  <FamilyName>Heufelder</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis</ArticleTitle>
                <JournalTitle>Arthritis Rheum</JournalTitle>
                <VolumeID>44</VolumeID>
                <FirstPage>253</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>11229454</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXitlCgtLk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hofbauer LC, Heufelder AE. The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum 2001;44:253–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_22">
              <CitationNumber>19</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WS</Initials>
                  <FamilyName>Simonet</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Lacey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CR</Initials>
                  <FamilyName>Dunstan</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Osteoprotegerin: a novel secreted protein involved in the regulation of bone density</ArticleTitle>
                <JournalTitle>Cell</JournalTitle>
                <VolumeID>89</VolumeID>
                <FirstPage>309</FirstPage>
                <LastPage>19</LastPage>
                <Occurrence Type="PID">
                  <Handle>9108485</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXislCgtLc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309–19.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_22">
              <CitationNumber>20</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Tsuda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Goto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Mochizuki</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis</ArticleTitle>
                <JournalTitle>Biochem Biophys Res Commun</JournalTitle>
                <VolumeID>234</VolumeID>
                <FirstPage>137</FirstPage>
                <LastPage>42</LastPage>
                <Occurrence Type="PID">
                  <Handle>9168977</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXjt1ynsLw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tsuda E, Goto M, Mochizuki S, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997;234:137–42.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_22">
              <CitationNumber>21</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Nagai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Sato</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation</ArticleTitle>
                <JournalTitle>Biochem Biophys Res Commun</JournalTitle>
                <VolumeID>257</VolumeID>
                <FirstPage>719</FirstPage>
                <LastPage>23</LastPage>
                <Occurrence Type="PID">
                  <Handle>10208850</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXisVaiurk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nagai M, Sato N. Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation. Biochem Biophys Res Commun 1999;257:719–23.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_22">
              <CitationNumber>22</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LC</Initials>
                  <FamilyName>Hofbauer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CR</Initials>
                  <FamilyName>Dunstan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TC</Initials>
                  <FamilyName>Spelsberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BL</Initials>
                  <FamilyName>Riggs</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Khosla</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines</ArticleTitle>
                <JournalTitle>Biochem Biophys Res Commun</JournalTitle>
                <VolumeID>250</VolumeID>
                <FirstPage>776</FirstPage>
                <LastPage>81</LastPage>
                <Occurrence Type="PID">
                  <Handle>9784422</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXmsF2qtr4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 1998;250:776–81.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_22">
              <CitationNumber>23</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GD</Initials>
                  <FamilyName>Roodman</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Cell biology of the osteoclast</ArticleTitle>
                <JournalTitle>Exp Hematol</JournalTitle>
                <VolumeID>27</VolumeID>
                <FirstPage>1229</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="PID">
                  <Handle>10428500</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1MzlsFCmtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Roodman GD. Cell biology of the osteoclast. Exp Hematol 1999;27:1229–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_22">
              <CitationNumber>24</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Katunuma</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Mechanism and regulation of bone resorption by osteoclasts</ArticleTitle>
                <JournalTitle>Curr Top Cell Regul</JournalTitle>
                <VolumeID>35</VolumeID>
                <FirstPage>179</FirstPage>
                <LastPage>92</LastPage>
                <Occurrence Type="PID">
                  <Handle>9192181</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXjslSks78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Katunuma N. Mechanism and regulation of bone resorption by osteoclasts. Curr Top Cell Regul 1997;35:179–92.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_22">
              <CitationNumber>25</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Kiviranta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Morko</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Uusitalo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HT</Initials>
                  <FamilyName>Aro</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Vuorio</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Rantakokko</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K</ArticleTitle>
                <JournalTitle>J Bone Miner Res</JournalTitle>
                <VolumeID>16</VolumeID>
                <FirstPage>1444</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>11499867</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXmtVOhtb0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kiviranta R, Morko J, Uusitalo H, Aro HT, Vuorio E, Rantakokko J. Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J Bone Miner Res 2001;16:1444–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_22">
              <CitationNumber>26</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Gowen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Lazner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Dodds</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization</ArticleTitle>
                <JournalTitle>J Bone Miner Res</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>1654</FirstPage>
                <LastPage>63</LastPage>
                <Occurrence Type="PID">
                  <Handle>10491212</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXmsFOis7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gowen M, Lazner F, Dodds R, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 1999;14:1654–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_22">
              <CitationNumber>27</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BS</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LS</Initials>
                  <FamilyName>Holliday</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Ojikutu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Krits</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Gluck</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Osteoclasts express the B2 isoform of vacuolar H(+)-ATPase intracellularly and on their plasma membranes</ArticleTitle>
                <JournalTitle>Am J Physiol</JournalTitle>
                <VolumeID>270</VolumeID>
                <FirstPage>C382</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>8772466</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XhtVygu7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lee BS, Holliday LS, Ojikutu B, Krits I, Gluck SL. Osteoclasts express the B2 isoform of vacuolar H(+)-ATPase intracellularly and on their plasma membranes. Am J Physiol 1996;270:C382–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_22">
              <CitationNumber>28</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Lehenkari</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TA</Initials>
                  <FamilyName>Hentunen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Laitala-Leinonen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Tuukkanen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HK</Initials>
                  <FamilyName>Vaananen</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Carbonic anhydrase II plays a major role in osteoclast differentiation and bone resorption by effecting the steady state intracellular pH and Ca<Superscript>2+</Superscript>
                </ArticleTitle>
                <JournalTitle>Exp Cell Res</JournalTitle>
                <VolumeID>242</VolumeID>
                <FirstPage>128</FirstPage>
                <LastPage>37</LastPage>
                <Occurrence Type="PID">
                  <Handle>9665810</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXks1aks7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lehenkari P, Hentunen TA, Laitala-Leinonen T, Tuukkanen J, Vaananen HK. Carbonic anhydrase II plays a major role in osteoclast differentiation and bone resorption by effecting the steady state intracellular pH and Ca<Superscript>2+</Superscript>. Exp Cell Res 1998;242:128–37.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_22">
              <CitationNumber>29</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Lalande</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Roux</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Denne</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Indapamide, a thiazide-like diuretic, decreases bone resorption in vitro</ArticleTitle>
                <JournalTitle>J Bone Miner Res</JournalTitle>
                <VolumeID>16</VolumeID>
                <FirstPage>361</FirstPage>
                <LastPage>70</LastPage>
                <Occurrence Type="PID">
                  <Handle>11204436</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXptlyjsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lalande A, Roux S, Denne MA, et al. Indapamide, a thiazide-like diuretic, decreases bone resorption in vitro. J Bone Miner Res 2001;16:361–70.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_22">
              <CitationNumber>30</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GA</Initials>
                  <FamilyName>Rodan</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">The development and function of the skeleton and bone metastases</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>97</VolumeID>
                <FirstPage>726</FirstPage>
                <LastPage>32</LastPage>
                <Occurrence Type="PID">
                  <Handle>12548569</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rodan GA. The development and function of the skeleton and bone metastases. Cancer 2003;97:726–32.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_22">
              <CitationNumber>31</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PL</Initials>
                  <FamilyName>Munk</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PY</Initials>
                  <FamilyName>Poon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JX</Initials>
                  <FamilyName>O’Connell</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Osteoblastic metastases from breast carcinoma with false-negative bone scan</ArticleTitle>
                <JournalTitle>Skeletal Radiol</JournalTitle>
                <VolumeID>26</VolumeID>
                <FirstPage>434</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>9259104</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2svgtlOkuw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Munk PL, Poon PY, O’Connell JX, et al. Osteoblastic metastases from breast carcinoma with false-negative bone scan. Skeletal Radiol 1997;26:434–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_22">
              <CitationNumber>32</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Roudier</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Sherrard</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>True</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Heterogenous bone histomorphometric patterns in metastatic prostate cancer</ArticleTitle>
                <JournalTitle>J Bone Miner Res</JournalTitle>
                <VolumeID>15S1</VolumeID>
                <FirstPage>S567</FirstPage>
              </BibArticle>
              <BibUnstructured>Roudier M, Sherrard D, True L, et al. Heterogenous bone histomorphometric patterns in metastatic prostate cancer. J Bone Miner Res 2000;15S1:S567.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_22">
              <CitationNumber>33</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BI</Initials>
                  <FamilyName>Carlin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GL</Initials>
                  <FamilyName>Andriole</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>88</VolumeID>
                <FirstPage>2989</FirstPage>
                <LastPage>94</LastPage>
                <Occurrence Type="PID">
                  <Handle>10898342</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3czlsVOjtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000;88:2989–94.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_22">
              <CitationNumber>34</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TG</Initials>
                  <FamilyName>Hullinger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RS</Initials>
                  <FamilyName>Taichman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DA</Initials>
                  <FamilyName>Linseman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Somerman</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Secretory products from PC-3 and MCF-7 tumor cell lines upregulate osteopontin in MC3T3-E1 cells</ArticleTitle>
                <JournalTitle>J Cell Biochem</JournalTitle>
                <VolumeID>78</VolumeID>
                <FirstPage>607</FirstPage>
                <LastPage>16</LastPage>
                <Occurrence Type="PID">
                  <Handle>10861858</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXlvFOlu70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hullinger TG, Taichman RS, Linseman DA, Somerman MJ. Secretory products from PC-3 and MCF-7 tumor cell lines upregulate osteopontin in MC3T3-E1 cells. J Cell Biochem 2000;78:607–16.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_22">
              <CitationNumber>35</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Lalich</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DG</Initials>
                  <FamilyName>McNeel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Wilding</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Liu</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Endothelin receptor antagonists in cancer therapy</ArticleTitle>
                <JournalTitle>Cancer Invest</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>785</FirstPage>
                <LastPage>94</LastPage>
                <Occurrence Type="PID">
                  <Handle>18058475</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhtl2isrvL</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lalich M, McNeel DG, Wilding G, Liu G. Endothelin receptor antagonists in cancer therapy. Cancer Invest 2007;25:785–94.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_22">
              <CitationNumber>36</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Cornish</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KE</Initials>
                  <FamilyName>Callon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Lin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Xiao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Moseley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IR</Initials>
                  <FamilyName>Reid</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Stimulation of osteoblast proliferation by C-terminal fragments of parathyroid hormone-related protein</ArticleTitle>
                <JournalTitle>J Bone Miner Res</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>915</FirstPage>
                <LastPage>22</LastPage>
                <Occurrence Type="PID">
                  <Handle>10352099</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXjvFKqtbs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Cornish J, Callon KE, Lin C, Xiao C, Moseley JM, Reid IR. Stimulation of osteoblast proliferation by C-terminal fragments of parathyroid hormone-related protein. J Bone Miner Res 1999;14:915–22.</BibUnstructured>
            </Citation>
            <Citation ID="CR37_22">
              <CitationNumber>37</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Rabbani</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Gladu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AP</Initials>
                  <FamilyName>Mazar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Henkin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Goltzman</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase</ArticleTitle>
                <JournalTitle>J Cell Physiol</JournalTitle>
                <VolumeID>172</VolumeID>
                <FirstPage>137</FirstPage>
                <LastPage>45</LastPage>
                <Occurrence Type="PID">
                  <Handle>9258335</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXlt1Ggtb4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rabbani SA, Gladu J, Mazar AP, Henkin J, Goltzman D. Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase. J Cell Physiol 1997;172:137–45.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_22">
              <CitationNumber>38</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Honore</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NM</Initials>
                  <FamilyName>Luger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Sabino</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord</ArticleTitle>
                <JournalTitle>Nat Med</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>521</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>10802707</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXjtFyhsLw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Honore P, Luger NM, Sabino MA, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 2000;6:521–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR39_22">
              <CitationNumber>39</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Chiao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BS</Initials>
                  <FamilyName>Moonga</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>YM</Initials>
                  <FamilyName>Yang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>83</VolumeID>
                <FirstPage>360</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>10917552</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXlslens7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chiao JW, Moonga BS, Yang YM, et al. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer 2000;83:360–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR40_22">
              <CitationNumber>40</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Lin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CP</Initials>
                  <FamilyName>Tarnowski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>47</VolumeID>
                <FirstPage>212</FirstPage>
                <LastPage>21</LastPage>
                <Occurrence Type="PID">
                  <Handle>11351351</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXjvVamt78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lin DL, Tarnowski CP, Zhang J, et al. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 2001;47:212–21.</BibUnstructured>
            </Citation>
            <Citation ID="CR41_22">
              <CitationNumber>41</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Dai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Qi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone</ArticleTitle>
                <JournalTitle>J Clin Invest</JournalTitle>
                <VolumeID>107</VolumeID>
                <FirstPage>1235</FirstPage>
                <LastPage>44</LastPage>
                <Occurrence Type="PID">
                  <Handle>11375413</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXjsl2ntr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR42_22">
              <CitationNumber>42</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Brown</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Corey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ZD</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Osteoprotegerin and rank ligand expression in prostate cancer</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>57</VolumeID>
                <FirstPage>611</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>11306358</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3M3ms1WrsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Brown JM, Corey E, Lee ZD, et al. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 2001;57:611–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR43_22">
              <CitationNumber>43</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>FC</Initials>
                  <FamilyName>Perez-Martinez</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Alonso</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Sarasa</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Receptor activator of nuclear factor-kappaB ligand (RANKL) as a novel prognostic marker in prostate carcinoma</ArticleTitle>
                <JournalTitle>Histol Histopathol</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>709</FirstPage>
                <LastPage>15</LastPage>
                <Occurrence Type="PID">
                  <Handle>18366009</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Perez-Martinez FC, Alonso V, Sarasa JL, et al. Receptor activator of nuclear factor-kappaB ligand (RANKL) as a novel prognostic marker in prostate carcinoma. Histol Histopathol 2008;23:709–15.</BibUnstructured>
            </Citation>
            <Citation ID="CR44_22">
              <CitationNumber>44</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Sircar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Aprikian</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Potti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Goltzman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Rabbani</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>107</VolumeID>
                <FirstPage>289</FirstPage>
                <LastPage>98</LastPage>
                <Occurrence Type="PID">
                  <Handle>16752412</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xnsl2mtL0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 2006;107:289–98.</BibUnstructured>
            </Citation>
            <Citation ID="CR45_22">
              <CitationNumber>45</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Brown</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Vessella</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Kostenuik</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CR</Initials>
                  <FamilyName>Dunstan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PH</Initials>
                  <FamilyName>Lange</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Corey</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Serum osteoprotegerin levels are increased in patients with advanced prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>7</VolumeID>
                <FirstPage>2977</FirstPage>
                <LastPage>83</LastPage>
                <Occurrence Type="PID">
                  <Handle>11595685</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXnvF2ktbc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Brown JM, Vessella RL, Kostenuik PJ, Dunstan CR, Lange PH, Corey E. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 2001;7:2977–83.</BibUnstructured>
            </Citation>
            <Citation ID="CR46_22">
              <CitationNumber>46</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Jung</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Stephan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Semjonow</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Lein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Schnorr</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Loening</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>170</VolumeID>
                <FirstPage>2302</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>14634401</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jung K, Stephan C, Semjonow A, Lein M, Schnorr D, Loening SA. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. J Urol 2003;170:2302–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR47_22">
              <CitationNumber>47</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Kiefer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Vessella</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Quinn</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft</ArticleTitle>
                <JournalTitle>Clin Exp Metastasis</JournalTitle>
                <VolumeID>21</VolumeID>
                <FirstPage>381</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>15672862</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXht1Khsr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kiefer JA, Vessella RL, Quinn JE, et al. The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clin Exp Metastasis 2004;21:381–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR48_22">
              <CitationNumber>48</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Dai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Yao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Lu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Dougall</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ET</Initials>
                  <FamilyName>Keller</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>63</VolumeID>
                <FirstPage>7883</FirstPage>
                <LastPage>90</LastPage>
                <Occurrence Type="PID">
                  <Handle>14633717</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXptFOlt7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res 2003;63:7883–90.</BibUnstructured>
            </Citation>
            <Citation ID="CR49_22">
              <CitationNumber>49</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Stearns</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice</ArticleTitle>
                <JournalTitle>Invasion Metastasis</JournalTitle>
                <VolumeID>16</VolumeID>
                <FirstPage>116</FirstPage>
                <LastPage>31</LastPage>
                <Occurrence Type="PID">
                  <Handle>9186547</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXktV2js78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Stearns ME, Wang M. Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Invasion Metastasis 1996;16:116–31.</BibUnstructured>
            </Citation>
            <Citation ID="CR50_22">
              <CitationNumber>50</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>John</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Tuszynski</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis</ArticleTitle>
                <JournalTitle>Pathol Oncol Res</JournalTitle>
                <VolumeID>7</VolumeID>
                <FirstPage>14</FirstPage>
                <LastPage>23</LastPage>
                <Occurrence Type="PID">
                  <Handle>11349215</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXlsFGjsbw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001;7:14–23.</BibUnstructured>
            </Citation>
            <Citation ID="CR51_22">
              <CitationNumber>51</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Festuccia</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Bologna</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Vicentini</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells</ArticleTitle>
                <JournalTitle>Int J Cancer</JournalTitle>
                <VolumeID>69</VolumeID>
                <FirstPage>386</FirstPage>
                <LastPage>93</LastPage>
                <Occurrence Type="PID">
                  <Handle>8900372</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28Xnt1KgtLw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Festuccia C, Bologna M, Vicentini C, et al. Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells. Int J Cancer 1996;69:386–93.</BibUnstructured>
            </Citation>
            <Citation ID="CR52_22">
              <CitationNumber>52</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Festuccia</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Giunciuglio</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Guerra</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion</ArticleTitle>
                <JournalTitle>Oncol Res</JournalTitle>
                <VolumeID>11</VolumeID>
                <FirstPage>17</FirstPage>
                <LastPage>31</LastPage>
                <Occurrence Type="PID">
                  <Handle>10451028</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXltVKmtrk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Festuccia C, Giunciuglio D, Guerra F, et al. Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion. Oncol Res 1999;11:17–31.</BibUnstructured>
            </Citation>
            <Citation ID="CR53_22">
              <CitationNumber>53</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Nabha</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EB</Initials>
                  <FamilyName>Santos</FamilyName>
                  <Particle>dos</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HA</Initials>
                  <FamilyName>Yamamoto</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an MMP-12 dependent manner</ArticleTitle>
                <JournalTitle>Int J Cancer</JournalTitle>
                <VolumeID>122</VolumeID>
                <FirstPage>2482</FirstPage>
                <LastPage>90</LastPage>
                <Occurrence Type="PID">
                  <Handle>18324629</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXltlaiuro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nabha SM, dos Santos EB, Yamamoto HA, et al. Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an MMP-12 dependent manner. Int J Cancer 2008;122:2482–90.</BibUnstructured>
            </Citation>
            <Citation ID="CR54_22">
              <CitationNumber>54</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WC</Initials>
                  <FamilyName>Duivenvoorden</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HW</Initials>
                  <FamilyName>Hirte</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Singh</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells</ArticleTitle>
                <JournalTitle>Invasion Metastasis</JournalTitle>
                <VolumeID>17</VolumeID>
                <FirstPage>312</FirstPage>
                <LastPage>22</LastPage>
                <Occurrence Type="PID">
                  <Handle>9949290</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXhsl2itb4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Duivenvoorden WC, Hirte HW, Singh G. Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells. Invasion Metastasis 1997;17:312–22.</BibUnstructured>
            </Citation>
            <Citation ID="CR55_22">
              <CitationNumber>55</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>OH</Initials>
                  <FamilyName>Sanchez-Sweatman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FW</Initials>
                  <FamilyName>Orr</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Singh</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Human metastatic prostate PC3 cell lines degrade bone using matrix metalloproteinases</ArticleTitle>
                <JournalTitle>Invasion Metastasis</JournalTitle>
                <VolumeID>18</VolumeID>
                <FirstPage>297</FirstPage>
                <LastPage>305</LastPage>
                <Occurrence Type="PID">
                  <Handle>10729774</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXjvVamtbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sanchez-Sweatman OH, Orr FW, Singh G. Human metastatic prostate PC3 cell lines degrade bone using matrix metalloproteinases. Invasion Metastasis 1998;18:297–305.</BibUnstructured>
            </Citation>
            <Citation ID="CR56_22">
              <CitationNumber>56</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>Stratton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Sirvent</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TS</Initials>
                  <FamilyName>Udayakumar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RB</Initials>
                  <FamilyName>Nagle</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GT</Initials>
                  <FamilyName>Bowden</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Expression of the matrix metalloproteinase promatrilysin in coculture of prostate carcinoma cell lines</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>48</VolumeID>
                <FirstPage>206</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>11494336</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXmsVynuro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Stratton MS, Sirvent H, Udayakumar TS, Nagle RB, Bowden GT. Expression of the matrix metalloproteinase promatrilysin in coculture of prostate carcinoma cell lines. Prostate 2001;48:206–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR57_22">
              <CitationNumber>57</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PC</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hobish</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Lin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Culig</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ET</Initials>
                  <FamilyName>Keller</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Interleukin-6 and prostate cancer progression</ArticleTitle>
                <JournalTitle>Cytokine Growth Factor Rev</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>33</FirstPage>
                <LastPage>40</LastPage>
                <Occurrence Type="PID">
                  <Handle>11312117</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXjtFOhsbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Smith PC, Hobish A, Lin D, Culig Z, Keller ET. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 2001;12:33–40.</BibUnstructured>
            </Citation>
            <Citation ID="CR58_22">
              <CitationNumber>58</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Weber</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Mejia</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Bone</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Watson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Orr</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice</ArticleTitle>
                <JournalTitle>Eur J Cancer</JournalTitle>
                <VolumeID>37</VolumeID>
                <FirstPage>106</FirstPage>
                <LastPage>13</LastPage>
                <Occurrence Type="PID">
                  <Handle>11165137</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXntlOnug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lee J, Weber M, Mejia S, Bone E, Watson P, Orr W. A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice. Eur J Cancer 2001;37:106–13.</BibUnstructured>
            </Citation>
            <Citation ID="CR59_22">
              <CitationNumber>59</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Nemeth</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Yousif</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Herzog</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>94</VolumeID>
                <FirstPage>17</FirstPage>
                <LastPage>25</LastPage>
                <Occurrence Type="PID">
                  <Handle>11773278</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xit1amt7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nemeth JA, Yousif R, Herzog M, et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002;94:17–25.</BibUnstructured>
            </Citation>
            <Citation ID="CR60_22">
              <CitationNumber>60</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Stearns</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice</ArticleTitle>
                <JournalTitle>Clin Exp Metastasis</JournalTitle>
                <VolumeID>16</VolumeID>
                <FirstPage>693</FirstPage>
                <LastPage>702</LastPage>
                <Occurrence Type="PID">
                  <Handle>10211982</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXivFequ7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Stearns ME, Wang M. Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice. Clin Exp Metastasis 1998;16:693–702.</BibUnstructured>
            </Citation>
            <Citation ID="CR61_22">
              <CitationNumber>61</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Strewler</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">The physiology of parathyroid hormone-related protein</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>342</VolumeID>
                <FirstPage>177</FirstPage>
                <LastPage>85</LastPage>
                <Occurrence Type="PID">
                  <Handle>10639544</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXos1Olsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Strewler GJ. The physiology of parathyroid hormone-related protein. N Engl J Med 2000;342:177–85.</BibUnstructured>
            </Citation>
            <Citation ID="CR62_22">
              <CitationNumber>62</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Iwamura</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Abrahamsson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KA</Initials>
                  <FamilyName>Foss</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Wu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AT</Initials>
                  <FamilyName>Cockett</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LJ</Initials>
                  <FamilyName>Deftos</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>43</VolumeID>
                <FirstPage>675</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>8165768</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2c3hvFSltw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Iwamura M, Abrahamsson PA, Foss KA, Wu G, Cockett AT, Deftos LJ. Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. Urology 1994;43:675–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR63_22">
              <CitationNumber>63</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LJ</Initials>
                  <FamilyName>Deftos</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Prostate carcinoma: production of bioactive factors</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>88</VolumeID>
                <FirstPage>3002</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>10898344</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXksVCmsLo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Deftos LJ. Prostate carcinoma: production of bioactive factors. Cancer 2000;88:3002–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR64_22">
              <CitationNumber>64</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Iwamura</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Sant’Agnese</FamilyName>
                  <Particle>di</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Wu</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1993</Year>
                <ArticleTitle Language="En">Immunohistochemical localization of parathyroid hormone-related protein in human prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>53</VolumeID>
                <FirstPage>1724</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>8467485</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3s3itlWktw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Iwamura M, di Sant’Agnese PA, Wu G, et al. Immunohistochemical localization of parathyroid hormone-related protein in human prostate cancer. Cancer Res 1993;53:1724–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR65_22">
              <CitationNumber>65</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Asadi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Farraj</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Sharifi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Malakouti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Antar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Kukreja</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia</ArticleTitle>
                <JournalTitle>Hum Pathol</JournalTitle>
                <VolumeID>27</VolumeID>
                <FirstPage>1319</FirstPage>
                <LastPage>23</LastPage>
                <Occurrence Type="PID">
                  <Handle>8958305</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2s7hslagtA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Asadi F, Farraj M, Sharifi R, Malakouti S, Antar S, Kukreja S. Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia. Hum Pathol 1996;27:1319–23.</BibUnstructured>
            </Citation>
            <Citation ID="CR66_22">
              <CitationNumber>66</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Iwamura</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Gershagen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Lapets</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">Immunohistochemical localization of parathyroid hormone-related protein in prostatic intraepithelial neoplasia</ArticleTitle>
                <JournalTitle>Hum Pathol</JournalTitle>
                <VolumeID>26</VolumeID>
                <FirstPage>797</FirstPage>
                <LastPage>801</LastPage>
                <Occurrence Type="PID">
                  <Handle>7628854</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2MzlsFWhtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Iwamura M, Gershagen S, Lapets O, et al. Immunohistochemical localization of parathyroid hormone-related protein in prostatic intraepithelial neoplasia. Hum Pathol 1995;26:797–801.</BibUnstructured>
            </Citation>
            <Citation ID="CR67_22">
              <CitationNumber>67</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KM</Initials>
                  <FamilyName>Dougherty</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EA</Initials>
                  <FamilyName>Blomme</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Koh</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Parathyroid hormone-related protein as a growth regulator of prostate carcinoma</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>59</VolumeID>
                <FirstPage>6015</FirstPage>
                <LastPage>22</LastPage>
                <Occurrence Type="PID">
                  <Handle>10606251</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXht1Smuw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dougherty KM, Blomme EA, Koh AJ, et al. Parathyroid hormone-related protein as a growth regulator of prostate carcinoma. Cancer Res 1999;59:6015–22.</BibUnstructured>
            </Citation>
            <Citation ID="CR68_22">
              <CitationNumber>68</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Iddon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NJ</Initials>
                  <FamilyName>Bundred</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Hoyland</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Expression of parathyroid hormone-related protein and its receptor in bone metastases from prostate cancer</ArticleTitle>
                <JournalTitle>J Pathol</JournalTitle>
                <VolumeID>191</VolumeID>
                <FirstPage>170</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>10861577</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXksFShtb0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Iddon J, Bundred NJ, Hoyland J, et al. Expression of parathyroid hormone-related protein and its receptor in bone metastases from prostate cancer. J Pathol 2000;191:170–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR69_22">
              <CitationNumber>69</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Kremer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Goltzman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Amizuka</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MM</Initials>
                  <FamilyName>Webber</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JS</Initials>
                  <FamilyName>Rhim</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">ras Activation of human prostate epithelial cells induces overexpression of parathyroid hormone-related peptide</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>3</VolumeID>
                <FirstPage>855</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>9815759</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXkt1Ohs7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kremer R, Goltzman D, Amizuka N, Webber MM, Rhim JS. ras Activation of human prostate epithelial cells induces overexpression of parathyroid hormone-related peptide. Clin Cancer Res 1997;3:855–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR70_22">
              <CitationNumber>70</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Peehl</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MG</Initials>
                  <FamilyName>Edgar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SD</Initials>
                  <FamilyName>Cramer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LJ</Initials>
                  <FamilyName>Deftos</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Parathyroid hormone-related protein is not an autocrine growth factor for normal prostatic epithelial cells</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>31</VolumeID>
                <FirstPage>47</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>9108886</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXivFags78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Peehl DM, Edgar MG, Cramer SD, Deftos LJ. Parathyroid hormone-related protein is not an autocrine growth factor for normal prostatic epithelial cells. Prostate 1997;31:47–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR71_22">
              <CitationNumber>71</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EA</Initials>
                  <FamilyName>Blomme</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KM</Initials>
                  <FamilyName>Dougherty</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KJ</Initials>
                  <FamilyName>Pienta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CC</Initials>
                  <FamilyName>Capen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TJ</Initials>
                  <FamilyName>Rosol</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LK</Initials>
                  <FamilyName>McCauley</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Skeletal metastasis of prostate adenocarcinoma in rats: morphometric analysis and role of parathyroid hormone-related protein</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>39</VolumeID>
                <FirstPage>187</FirstPage>
                <LastPage>97</LastPage>
                <Occurrence Type="PID">
                  <Handle>10334108</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXjtVyqu74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Blomme EA, Dougherty KM, Pienta KJ, Capen CC, Rosol TJ, McCauley LK. Skeletal metastasis of prostate adenocarcinoma in rats: morphometric analysis and role of parathyroid hormone-related protein. Prostate 1999;39:187–97.</BibUnstructured>
            </Citation>
            <Citation ID="CR72_22">
              <CitationNumber>72</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>FC</Initials>
                  <FamilyName>Perez-Martinez</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Alonso</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Sarasa</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Immunohistochemical analysis of low-grade and high-grade prostate carcinoma: relative changes of parathyroid hormone-related protein and its parathyroid hormone 1 receptor, osteoprotegerin and receptor activator of nuclear factor-kB ligand</ArticleTitle>
                <JournalTitle>J Clin Pathol</JournalTitle>
                <VolumeID>60</VolumeID>
                <FirstPage>290</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>16775117</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXktlOrtrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Perez-Martinez FC, Alonso V, Sarasa JL, et al. Immunohistochemical analysis of low-grade and high-grade prostate carcinoma: relative changes of parathyroid hormone-related protein and its parathyroid hormone 1 receptor, osteoprotegerin and receptor activator of nuclear factor-kB ligand. J Clin Pathol 2007;60:290–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR73_22">
              <CitationNumber>73</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Rabbani</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Gladu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Harakidas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Jamison</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Goltzman</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Over-production of parathyroid hormone-related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo</ArticleTitle>
                <JournalTitle>Int J Cancer</JournalTitle>
                <VolumeID>80</VolumeID>
                <FirstPage>257</FirstPage>
                <LastPage>64</LastPage>
                <Occurrence Type="PID">
                  <Handle>9935208</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXhtlaktw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rabbani SA, Gladu J, Harakidas P, Jamison B, Goltzman D. Over-production of parathyroid hormone-related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo. Int J Cancer 1999;80:257–64.</BibUnstructured>
            </Citation>
            <Citation ID="CR74_22">
              <CitationNumber>74</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Lu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Xiao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Galson</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">PTHrP-induced MCP-1 production by human bone marrow endothelial cells and osteoblasts promotes osteoclast differentiation and prostate cancer cell proliferation and invasion in vitro</ArticleTitle>
                <JournalTitle>Int J Cancer</JournalTitle>
                <VolumeID>121</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>724</FirstPage>
                <LastPage>33</LastPage>
                <Occurrence Type="PID">
                  <Handle>17390372</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXotleqtbs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lu Y, Xiao G, Galson DL, et al. PTHrP-induced MCP-1 production by human bone marrow endothelial cells and osteoblasts promotes osteoclast differentiation and prostate cancer cell proliferation and invasion in vitro. Int J Cancer 2007;121(4):724–33.</BibUnstructured>
            </Citation>
            <Citation ID="CR75_22">
              <CitationNumber>75</CitationNumber>
              <BibChapter>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Sehgal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Rayanade</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Pan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Margulies</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ChapterTitle Language="En">Interleukin-6 type Cytokines</ChapterTitle>
                <BibEditorName>
                  <Initials>A</Initials>
                  <FamilyName>Mackiewicz</FamilyName>
                </BibEditorName>
                <BibEditorName>
                  <Initials>A</Initials>
                  <FamilyName>Koji</FamilyName>
                </BibEditorName>
                <BibEditorName>
                  <Initials>P</Initials>
                  <FamilyName>Sehgal</FamilyName>
                </BibEditorName>
                <Eds/>
                <BookTitle>Annals of the New York Academy of Sciences</BookTitle>
                <PublisherName>New York Academy of Sciences</PublisherName>
                <PublisherLocation>New York</PublisherLocation>
                <FirstPage>1</FirstPage>
                <LastPage>14</LastPage>
              </BibChapter>
              <BibUnstructured>Sehgal P, Wang L, Rayanade R, Pan H, Margulies L. Interleukin-6 type cytokines. In: Mackiewicz A, Koji A, Sehgal P, eds. Annals of the New York Academy of Sciences. New York: New York Academy of Sciences; 1995:1–14.</BibUnstructured>
            </Citation>
            <Citation ID="CR76_22">
              <CitationNumber>76</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Hirano</FamilyName>
                </BibAuthorName>
                <Year>1992</Year>
                <ArticleTitle Language="En">The biology of interleukin-6</ArticleTitle>
                <JournalTitle>Chem Immunol</JournalTitle>
                <VolumeID>51</VolumeID>
                <FirstPage>153</FirstPage>
                <LastPage>80</LastPage>
                <Occurrence Type="PID">
                  <Handle>1567541</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK38XksVKjur4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hirano T. The biology of interleukin-6. Chem Immunol 1992;51:153–80.</BibUnstructured>
            </Citation>
            <Citation ID="CR77_22">
              <CitationNumber>77</CitationNumber>
              <BibChapter>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Taga</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Hibi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Murakami</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1992</Year>
                <ChapterTitle Language="En">Interleukin-6 receptor and signals</ChapterTitle>
                <BibEditorName>
                  <Initials>T</Initials>
                  <FamilyName>Kishimoto</FamilyName>
                </BibEditorName>
                <Eds/>
                <BookTitle>Interleukins: Molecular Biology and Immunology, Chem Immunol</BookTitle>
                <PublisherName>Karger</PublisherName>
                <PublisherLocation>Basel</PublisherLocation>
                <FirstPage>181</FirstPage>
                <LastPage>204</LastPage>
              </BibChapter>
              <BibUnstructured>Taga T, Hibi M, Murakami M, et al. Interleukin-6 receptor and signals. In: Kishimoto T, ed. Interleukins: Molecular Biology and Immunology, Chem Immunol. Basel: Karger; 1992:181–204.</BibUnstructured>
            </Citation>
            <Citation ID="CR78_22">
              <CitationNumber>78</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Mullberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Oberthur</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Lottspeich</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1994</Year>
                <ArticleTitle Language="En">The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site</ArticleTitle>
                <JournalTitle>J Immunol</JournalTitle>
                <VolumeID>152</VolumeID>
                <FirstPage>4958</FirstPage>
                <LastPage>68</LastPage>
                <Occurrence Type="PID">
                  <Handle>8176214</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2c3jtV2ktg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mullberg J, Oberthur W, Lottspeich F, et al. The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol 1994;152:4958–68.</BibUnstructured>
            </Citation>
            <Citation ID="CR79_22">
              <CitationNumber>79</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Rose-John</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PC</Initials>
                  <FamilyName>Heinrich</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Soluble receptors for cytokines and growth factors: generation and biological function</ArticleTitle>
                <JournalTitle>Biochem J</JournalTitle>
                <VolumeID>300</VolumeID>
                <FirstPage>281</FirstPage>
                <LastPage>90</LastPage>
                <Occurrence Type="PID">
                  <Handle>8002928</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXktlalsLw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 1994;300:281–90.</BibUnstructured>
            </Citation>
            <Citation ID="CR80_22">
              <CitationNumber>80</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Lust</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KA</Initials>
                  <FamilyName>Donovan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MP</Initials>
                  <FamilyName>Kline</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PR</Initials>
                  <FamilyName>Greipp</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RA</Initials>
                  <FamilyName>Kyle</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NJ</Initials>
                  <FamilyName>Maihle</FamilyName>
                </BibAuthorName>
                <Year>1992</Year>
                <ArticleTitle Language="En">Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor</ArticleTitle>
                <JournalTitle>Cytokine</JournalTitle>
                <VolumeID>4</VolumeID>
                <FirstPage>96</FirstPage>
                <LastPage>100</LastPage>
                <Occurrence Type="PID">
                  <Handle>1633265</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXivFSnug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lust JA, Donovan KA, Kline MP, Greipp PR, Kyle RA, Maihle NJ. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 1992;4:96–100.</BibUnstructured>
            </Citation>
            <Citation ID="CR81_22">
              <CitationNumber>81</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Mackiewicz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Schooltink</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PC</Initials>
                  <FamilyName>Heinrich</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Rose-John</FamilyName>
                </BibAuthorName>
                <Year>1992</Year>
                <ArticleTitle Language="En">Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins</ArticleTitle>
                <JournalTitle>J Immunol</JournalTitle>
                <VolumeID>149</VolumeID>
                <FirstPage>2021</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>1381393</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXitVKrug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S. Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol 1992;149:2021–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR82_22">
              <CitationNumber>82</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HL</Initials>
                  <FamilyName>Adler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>McCurdy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MW</Initials>
                  <FamilyName>Kattan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TL</Initials>
                  <FamilyName>Timme</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PT</Initials>
                  <FamilyName>Scardino</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TC</Initials>
                  <FamilyName>Thompson</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>161</VolumeID>
                <FirstPage>182</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>10037394</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXitFarsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 1999;161:182–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR83_22">
              <CitationNumber>83</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Hoosien</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Abdul</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>McCabe</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer</ArticleTitle>
                <JournalTitle>Urol Oncol</JournalTitle>
                <VolumeID>1</VolumeID>
                <FirstPage>246</FirstPage>
                <LastPage>51</LastPage>
              </BibArticle>
              <BibUnstructured>Hoosien N, Abdul M, McCabe R, et al. Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer. Urol Oncol 1995;1:246–51.</BibUnstructured>
            </Citation>
            <Citation ID="CR84_22">
              <CitationNumber>84</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DA</Initials>
                  <FamilyName>Twillie</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Eisenberger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Carducci</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WS</Initials>
                  <FamilyName>Hseih</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WY</Initials>
                  <FamilyName>Kim</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Simons</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Interleukin-6: a candidate mediator of human prostate cancer morbidity</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>45</VolumeID>
                <FirstPage>542</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>7879350</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2M7osFSgtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 1995;45:542–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR85_22">
              <CitationNumber>85</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DE</Initials>
                  <FamilyName>Drachenberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AA</Initials>
                  <FamilyName>Elgamal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Rowbotham</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Peterson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GP</Initials>
                  <FamilyName>Murphy</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>41</VolumeID>
                <FirstPage>127</FirstPage>
                <LastPage>33</LastPage>
                <Occurrence Type="PID">
                  <Handle>10477909</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXmsFKrsb8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999;41:127–33.</BibUnstructured>
            </Citation>
            <Citation ID="CR86_22">
              <CitationNumber>86</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AS</Initials>
                  <FamilyName>Tsingotjidou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Zotalis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KR</Initials>
                  <FamilyName>Jackson</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Development of an animal model for prostate cancer cell metastasis to adult human bone</ArticleTitle>
                <JournalTitle>Anticancer Res</JournalTitle>
                <VolumeID>21</VolumeID>
                <FirstPage>971</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>11396190</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3MzivVyiug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tsingotjidou AS, Zotalis G, Jackson KR, et al. Development of an animal model for prostate cancer cell metastasis to adult human bone. Anticancer Res 2001;21:971–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR87_22">
              <CitationNumber>87</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Siegsmund</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Yamazaki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Pastan</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>151</VolumeID>
                <FirstPage>1396</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>7512667</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2c3htVKlsw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Siegsmund MJ, Yamazaki H, Pastan I. Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. J Urol 1994;151:1396–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR88_22">
              <CitationNumber>88</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hobisch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Rogatsch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hittmair</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue</ArticleTitle>
                <JournalTitle>J Pathol</JournalTitle>
                <VolumeID>191</VolumeID>
                <FirstPage>239</FirstPage>
                <LastPage>44</LastPage>
                <Occurrence Type="PID">
                  <Handle>10878544</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXltlygsrk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hobisch A, Rogatsch H, Hittmair A, et al. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 2000;191:239–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR89_22">
              <CitationNumber>89</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WB</Initials>
                  <FamilyName>Ershler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ET</Initials>
                  <FamilyName>Keller</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty [In Process Citation]</ArticleTitle>
                <JournalTitle>Annu Rev Med</JournalTitle>
                <VolumeID>51</VolumeID>
                <FirstPage>245</FirstPage>
                <LastPage>70</LastPage>
                <Occurrence Type="PID">
                  <Handle>10774463</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXisVelsbY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty [In Process Citation]. Annu Rev Med 2000;51:245–70.</BibUnstructured>
            </Citation>
            <Citation ID="CR90_22">
              <CitationNumber>90</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Jilka</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Passeri</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Girasole</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">Estrogen loss upregulates hematopoiesis in the mouse: a mediating role of IL-6</ArticleTitle>
                <JournalTitle>Exp Hematol</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>500</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>7768305</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXmsVKhtL0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jilka RL, Passeri G, Girasole G, et al. Estrogen loss upregulates hematopoiesis in the mouse: a mediating role of IL-6. Exp Hematol 1995;23:500–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR91_22">
              <CitationNumber>91</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>O’Brien</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SC</Initials>
                  <FamilyName>Lin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Bellido</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SC</Initials>
                  <FamilyName>Manolagas</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Expression levels of gp130 in bone marrow stromal cells determine the magnitude of osteoclastogenic signals generated by IL-6-type cytokines</ArticleTitle>
                <JournalTitle>J Cell Biochem</JournalTitle>
                <VolumeID>79</VolumeID>
                <FirstPage>532</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="PID">
                  <Handle>10996844</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>O’Brien CA, Lin SC, Bellido T, Manolagas SC. Expression levels of gp130 in bone marrow stromal cells determine the magnitude of osteoclastogenic signals generated by IL-6-type cytokines. J Cell Biochem 2000;79:532–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR92_22">
              <CitationNumber>92</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LC</Initials>
                  <FamilyName>Hofbauer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Lacey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CR</Initials>
                  <FamilyName>Dunstan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TC</Initials>
                  <FamilyName>Spelsberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BL</Initials>
                  <FamilyName>Riggs</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Khosla</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin- 6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells</ArticleTitle>
                <JournalTitle>Bone</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>255</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>10495128</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXls1Wiu78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin- 6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999;25:255–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR93_22">
              <CitationNumber>93</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Greenfield</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Shaw</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Gornik</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Banks</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption</ArticleTitle>
                <JournalTitle>J Clin Invest</JournalTitle>
                <VolumeID>96</VolumeID>
                <FirstPage>1238</FirstPage>
                <LastPage>44</LastPage>
                <Occurrence Type="PID">
                  <Handle>7657797</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2Mzos1KktQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Greenfield EM, Shaw SM, Gornik SA, Banks MA. Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption. J Clin Invest 1995;96:1238–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR94_22">
              <CitationNumber>94</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Mata</FamilyName>
                  <Particle>de la</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HL</Initials>
                  <FamilyName>Uy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TA</Initials>
                  <FamilyName>Guise</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo</ArticleTitle>
                <JournalTitle>J Clin Invest</JournalTitle>
                <VolumeID>95</VolumeID>
                <FirstPage>2846</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>7769125</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>de la Mata J, Uy HL, Guise TA, et al. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest 1995;95:2846–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR95_22">
              <CitationNumber>95</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PC</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ET</Initials>
                  <FamilyName>Keller</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>48</VolumeID>
                <FirstPage>47</FirstPage>
                <LastPage>53</LastPage>
                <Occurrence Type="PID">
                  <Handle>11391686</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXltVOgsrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Smith PC, Keller ET. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 2001;48:47–53.</BibUnstructured>
            </Citation>
            <Citation ID="CR96_22">
              <CitationNumber>96</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Bentley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FC</Initials>
                  <FamilyName>Hamdy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KA</Initials>
                  <FamilyName>Hart</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1992</Year>
                <ArticleTitle Language="En">Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>66</VolumeID>
                <FirstPage>1159</FirstPage>
                <LastPage>63</LastPage>
                <Occurrence Type="PID">
                  <Handle>1280991</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3s%2FptVKkuw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bentley H, Hamdy FC, Hart KA, et al. Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 1992;66:1159–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR97_22">
              <CitationNumber>97</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SP</Initials>
                  <FamilyName>Hedican</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>George</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1995</Year>
                <ArticleTitle Language="En">Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate</ArticleTitle>
                <JournalTitle>Nat Med</JournalTitle>
                <VolumeID>1</VolumeID>
                <FirstPage>944</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>7585222</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXnvVyrtb8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:944–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR98_22">
              <CitationNumber>98</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Carducci</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">The role of endothelin-1 and endothelin receptor antagonists in prostate cancer</ArticleTitle>
                <JournalTitle>BJU Int</JournalTitle>
                <VolumeID>85</VolumeID>
                <IssueID>Suppl 2</IssueID>
                <FirstPage>45</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>10781185</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXivFOhsr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nelson JB, Carducci MA. The role of endothelin-1 and endothelin receptor antagonists in prostate cancer. BJU Int 2000;85(Suppl 2):45–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR99_22">
              <CitationNumber>99</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BE</Initials>
                  <FamilyName>LeRoy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RS</Initials>
                  <FamilyName>Sellers</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TJ</Initials>
                  <FamilyName>Rosol</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Canine prostate stimulates osteoblast function using the endothelin receptors</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>59</VolumeID>
                <FirstPage>148</FirstPage>
                <LastPage>56</LastPage>
                <Occurrence Type="PID">
                  <Handle>15042615</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXktl2ls7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>LeRoy BE, Sellers RS, Rosol TJ. Canine prostate stimulates osteoblast function using the endothelin receptors. Prostate 2004;59:148–56.</BibUnstructured>
            </Citation>
            <Citation ID="CR100_22">
              <CitationNumber>100</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Jimeno</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Carducci</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Atrasentan: targeting the endothelin axis in prostate cancer</ArticleTitle>
                <JournalTitle>Expert Opin Investig Drugs</JournalTitle>
                <VolumeID>13</VolumeID>
                <FirstPage>1631</FirstPage>
                <LastPage>40</LastPage>
                <Occurrence Type="PID">
                  <Handle>15566319</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhtVahs7%2FF</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jimeno A, Carducci M. Atrasentan: targeting the endothelin axis in prostate cancer. Expert Opin Investig Drugs 2004;13:1631–40.</BibUnstructured>
            </Citation>
            <Citation ID="CR101_22">
              <CitationNumber>101</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Pirtskhalaishvili</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Endothelium-derived factors as paracrine mediators of prostate cancer progression</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>44</VolumeID>
                <FirstPage>77</FirstPage>
                <LastPage>87</LastPage>
                <Occurrence Type="PID">
                  <Handle>10861760</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXksVCru7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 2000;44:77–87.</BibUnstructured>
            </Citation>
            <Citation ID="CR102_22">
              <CitationNumber>102</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>VS</Initials>
                  <FamilyName>Perkel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Mohan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Baylink</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TA</Initials>
                  <FamilyName>Linkhart</FamilyName>
                </BibAuthorName>
                <Year>1990</Year>
                <ArticleTitle Language="En">An inhibitory insulin-like growth factor binding protein (In-IGFBP) from human prostatic cell conditioned medium reveals N-terminal sequence identity with bone derived In-IGFBP</ArticleTitle>
                <JournalTitle>J Clin Endocrinol Metabol</JournalTitle>
                <VolumeID>71</VolumeID>
                <FirstPage>533</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3cXlsVGqtLY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Perkel VS, Mohan S, Baylink DJ, Linkhart TA. An inhibitory insulin-like growth factor binding protein (In-IGFBP) from human prostatic cell conditioned medium reveals N-terminal sequence identity with bone derived In-IGFBP. J Clin Endocrinol Metabol 1990;71:533–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR103_22">
              <CitationNumber>103</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Taguchi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Yamamoto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Yamate</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage</ArticleTitle>
                <JournalTitle>Proc Assoc Am Physicians</JournalTitle>
                <VolumeID>110</VolumeID>
                <FirstPage>559</FirstPage>
                <LastPage>74</LastPage>
                <Occurrence Type="PID">
                  <Handle>9824538</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXnsFCqs74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Taguchi Y, Yamamoto M, Yamate T, et al. Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage. Proc Assoc Am Physicians 1998;110:559–74.</BibUnstructured>
            </Citation>
            <Citation ID="CR104_22">
              <CitationNumber>104</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Brun</FamilyName>
                  <Particle>Le</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Aubin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Soliman</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Upregulation of endothelin 1 and its precursor by IL-1beta, TNF-alpha, and TGF-beta in the PC3 human prostate cancer cell line</ArticleTitle>
                <JournalTitle>Cytokine</JournalTitle>
                <VolumeID>11</VolumeID>
                <FirstPage>157</FirstPage>
                <LastPage>62</LastPage>
                <Occurrence Type="PID">
                  <Handle>10089138</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Le Brun G, Aubin P, Soliman H, et al. Upregulation of endothelin 1 and its precursor by IL-1beta, TNF-alpha, and TGF-beta in the PC3 human prostate cancer cell line. Cytokine 1999;11:157–62.</BibUnstructured>
            </Citation>
            <Citation ID="CR105_22">
              <CitationNumber>105</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TA</Initials>
                  <FamilyName>Guise</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Molecular mechanisms of osteolytic bone metastases</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>88</VolumeID>
                <FirstPage>2892</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>10898330</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXksVCms7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer 2000;88:2892–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR106_22">
              <CitationNumber>106</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AC</Initials>
                  <FamilyName>Karaplis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Vautour</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Parathyroid hormone-related peptide and the parathyroid hormone/parathyroid hormone-related peptide receptor in skeletal development</ArticleTitle>
                <JournalTitle>Curr Opin Nephrol Hypertens</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>308</FirstPage>
                <LastPage>13</LastPage>
                <Occurrence Type="PID">
                  <Handle>9263678</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2svgvFejsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Karaplis AC, Vautour L. Parathyroid hormone-related peptide and the parathyroid hormone/parathyroid hormone-related peptide receptor in skeletal development. Curr Opin Nephrol Hypertens 1997;6:308–13.</BibUnstructured>
            </Citation>
            <Citation ID="CR107_22">
              <CitationNumber>107</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Killian</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DA</Initials>
                  <FamilyName>Corral</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Kawinski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RI</Initials>
                  <FamilyName>Constantine</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors</ArticleTitle>
                <JournalTitle>Biochem Biophys Res Commun</JournalTitle>
                <VolumeID>192</VolumeID>
                <FirstPage>940</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>7683467</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXktVKisr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Killian CS, Corral DA, Kawinski E, Constantine RI. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 1993;192:940–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR108_22">
              <CitationNumber>108</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Goltzman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AC</Initials>
                  <FamilyName>Karaplis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Kremer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Rabbani</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Molecular basis of the spectrum of skeletal complications of neoplasia</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>88</VolumeID>
                <FirstPage>2903</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>10898332</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXksVCms7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Goltzman D, Karaplis AC, Kremer R, Rabbani SA. Molecular basis of the spectrum of skeletal complications of neoplasia. Cancer 2000;88:2903–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR109_22">
              <CitationNumber>109</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Dai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Kitagawa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>64</VolumeID>
                <FirstPage>994</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>14871830</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhtFCgurg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dai J, Kitagawa Y, Zhang J, et al. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 2004;64:994–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR110_22">
              <CitationNumber>110</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CL</Initials>
                  <FamilyName>Hall</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Bafico</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Dai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Aaronson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ET</Initials>
                  <FamilyName>Keller</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Prostate cancer cells promote osteoblastic bone metastases through Wnts</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>65</VolumeID>
                <FirstPage>7554</FirstPage>
                <LastPage>60</LastPage>
                <Occurrence Type="PID">
                  <Handle>16140917</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXpslaitL4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 2005;65:7554–60.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
